Use of nicotinamide to treat hyperphosphatemia in dialysis patients. - Wikidata - awgldk - TriplyDB

Use of nicotinamide to treat hyperphosphatemia in dialysis patients.

Use of nicotinamide to treat hyperphosphatemia in dialysis patients.

http://www.wikidata.org/entity/Q37199788

about

N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin Vascular calcification: When should we interfere in chronic kidney disease patients and how?Stop chronic kidney disease progression: Time is approaching Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.Next-generation phosphate binders: focus on iron-based binders.Contemporary management of phosphorus retention in chronic kidney disease: a review.The role of phosphate in kidney disease.Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.Lowering Expectations with Niacin Treatment for CKD-MBD.Nicotinic acid and related compounds: A meta-analysis of their use for hyperphosphatemia in dialysis patients.

P2860

Q28069862-C4112D3E-AF99-4DB0-BB23-7A41825510A2 Q28071582-87F11CD0-D583-4528-BD4F-B8EB1E9071E2 Q28078020-5876028C-BCD4-456B-AD64-85679A051B4C Q33432308-E2207164-D751-4C3A-9F68-DFDB7311F4C9 Q38213502-F21A6DCE-5365-49E6-B132-5387AA8C3C28 Q38511621-2F1064EC-00EF-4001-8A00-B8E5DA09C9B7 Q38793054-3388061E-8BDF-4AEC-9848-05A0D33DB509 Q46799066-B4ED2DFB-25F3-4DA4-A398-F0A3B837490E Q50059026-FC3B351C-BADE-47B4-B533-D10C86B72A22 Q55035309-E651B50D-DBA1-4BF0-90DA-2AF1506C50D8

P2860

Use of nicotinamide to treat hyperphosphatemia in dialysis patients.

http://www.wikidata.org/entity/Q37199788

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Use of nicotinamide to treat hyperphosphatemia in dialysis patients.

@en

Use of nicotinamide to treat hyperphosphatemia in dialysis patients.

@nl

type

label

Use of nicotinamide to treat hyperphosphatemia in dialysis patients.

@en

Use of nicotinamide to treat hyperphosphatemia in dialysis patients.

@nl

prefLabel

Use of nicotinamide to treat hyperphosphatemia in dialysis patients.

@en

Use of nicotinamide to treat hyperphosphatemia in dialysis patients.

@nl

P1433

Q37199788-FAE5C3BD-E842-4D1D-BD5B-24297CB09CFB

P1476

Q37199788-9AB5D0FA-4BB0-4F82-B7C1-0028C6BA5C64

P2093

Q37199788-0294924F-56A0-4583-9664-04237B19CAA4

Q37199788-09F6165D-18D5-4890-B6B0-5BCB9D2AA4CC

Q37199788-3096E511-D9AB-49A9-8D7C-C7B6E89449FE

Q37199788-A75C052E-5258-4FA7-AC15-827FBB457D4B

Q37199788-B28ECBAE-EBEB-40AF-99B2-9B1E51E8BC26

Q37199788-C296E4E9-64A0-4AB2-8F44-88F57C9711E6

P2860

Q37199788-050CF664-7242-4F2C-B74B-0DA465B87181

Q37199788-0771090E-BCC0-4BB8-A454-7FAD0954982B

Q37199788-0EDE450F-3BE9-4D9D-B489-EDF079115208

Q37199788-102D5D16-3133-4047-BF8E-2F09677464A0

Q37199788-1DBB4913-CA2E-497D-90D4-87E5AF466683

Q37199788-268385C7-DC0A-4BE7-9892-8FEE1ED1130D

Q37199788-292D1603-030C-47B5-BBAF-950802532560

Q37199788-2FF19C05-5354-4CCD-A4F8-65503F3ECC99

Q37199788-36CC97DA-D9B7-4ACB-A8D4-5C83150C1BE0

Q37199788-3BF7826C-DC1E-4208-B267-640E87E76E47

P304

Q37199788-8521318B-4FC8-4441-82F2-DA83492AA555

P31

Q37199788-875EF067-82E8-4828-95EB-92E00C003D85

Q37199788-A15F3C1F-0798-4AC0-89F8-28B9064D40E2

P356

Q37199788-14B2D82D-BC52-442B-9801-E1CF975924C8

P433

Q37199788-170CF077-C1CB-4FD0-976A-ADB437F76C80

P478

Q37199788-CBBF6A23-C1E4-46E2-B035-4940502A795F

P577

Q37199788-F3E96B08-CFFF-4050-A729-A09E0F73EA32

P5875

Q37199788-6BFE8F6D-10F1-4C01-9074-91CB07C2C903

P698

Q37199788-0668F426-7B3D-4B65-A334-477EB6535BCD

P921

Q37199788-B6702855-8C7C-4A83-94DC-A4555D2B16ED

Q37199788-F5EE9110-D321-4539-BE69-D16AC0ED8423

P932

Q37199788-01A63D31-E1B8-4157-8634-991EEE6FCD1B

P356

S40268-013-0024-6

P1433

P1476

Use of nicotinamide to treat hyperphosphatemia in dialysis patients.

@en

P2093

Albert Fournier

http://www.w3.org/2001/XMLSchema#string

Aurélie Lenglet

http://www.w3.org/2001/XMLSchema#string

Michel Brazier

http://www.w3.org/2001/XMLSchema#string

Pauline Guffroy

http://www.w3.org/2001/XMLSchema#string

Sophie Liabeuf

http://www.w3.org/2001/XMLSchema#string

Ziad A Massy

http://www.w3.org/2001/XMLSchema#string

P2860

Oral phosphate binders in patients with kidney failure

Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring

Measurement of nicotinamide and N-methyl-2-pyridone-5-carboxamide in plasma by high performance liquid chromatography.

Niacin and analogs for phosphate control in dialysis--perspective from a developing country.

Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial.

Intestinal npt2b plays a major role in phosphate absorption and homeostasis.

Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.

Safety of high-dose nicotinamide: a review.

Cellular toxicity of nicotinamide metabolites.

Pharmacology, efficacy and safety of oral phosphate binders.

P304

165-173

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40268-013-0024-6

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256378315

http://www.w3.org/2001/XMLSchema#string

P698

24000048

http://www.w3.org/2001/XMLSchema#string

P921

hyperphosphatemia

P932

3784056

http://www.w3.org/2001/XMLSchema#string